<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00601406</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000581139</org_study_id>
    <secondary_id>CHNT-RAPPER</secondary_id>
    <secondary_id>EU-20798</secondary_id>
    <nct_id>NCT00601406</nct_id>
  </id_info>
  <brief_title>Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer</brief_title>
  <official_title>Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy (RAPPER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help&#xD;
      doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.&#xD;
      It may also help doctors predict how patients will respond to treatment.&#xD;
&#xD;
      PURPOSE: This clinical trial is evaluating DNA mutations in predicting the effect of&#xD;
      external-beam radiation therapy in patients with early breast cancer, localized prostate&#xD;
      cancer, or gynecologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To test the hypothesis that an association between common genetic variations, reported&#xD;
           by single nucleotide polymorphisms (SNP) in relevant candidate genes, is associated with&#xD;
           individual patient variability in normal tissue radiation response and toxicity.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare different clinical scoring systems for late normal tissue effects,&#xD;
           specifically Late Effect of Normal Tissue Subjective Objective Management Analysis (LENT&#xD;
           SOMA), Radiation Therapy Oncology Group (RTOG), quality of life, and in a subset common&#xD;
           terminology criteria (CTC) version 3.&#xD;
&#xD;
        -  To compare clinical scoring systems with analytical measures of normal tissue outcome in&#xD;
           a minority of patients, using volume change in the breast measured by laser camera.&#xD;
&#xD;
        -  To correlate family history information with SNP analysis to produce a polymorphism risk&#xD;
           score (PRS) for family history.&#xD;
&#xD;
        -  To compare a detailed 3D dose-volume analysis in a subset of patients with late effects&#xD;
           and SNP results.&#xD;
&#xD;
        -  To correlate actuarial analysis of late effects changes over time with PRS.&#xD;
&#xD;
        -  To conduct PRS analyses against tumor control probability (TCP), using survival as a&#xD;
           surrogate for TCP where necessary, and normal tissue complications vs tumor control&#xD;
           probability.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients are recruited from clinical trials in which their late normal tissue effects have&#xD;
      been measured. Blood samples are collected from these patients for analysis of genetic&#xD;
      variation by DNA extraction and single nucleotide polymorphism analysis. Sixty different&#xD;
      genes, including those involved in cell cycle checkpoint control, DNA damage recognition and&#xD;
      repair, induction of apoptosis, and cytokine production (including TGFÎ² pathways) are&#xD;
      assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Anticipated">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of association between common genetic variations, reported by single nucleotide polymorphisms (SNP) in relevant candidate genes, with individual patient variability in normal tissue radiation response and toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of different clinical scoring systems for late normal tissue effects</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of clinical scoring systems with analytical measures of normal tissue outcome using volume change in the breast measured by laser camera</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of family history information with SNP analysis to produce a polymorphism risk score (PRS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of detailed 3D dose-volume analysis with late effects and SNP results</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of actuarial analysis of late effects changes over time with PRS</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRS analyses against tumor control probability (TCP), using survival as a surrogate for TCP where necessary, and normal tissue complications vs tumor control probability</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Vaginal Cancer</condition>
  <condition>Vulvar Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene rearrangement analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Patients must have received curative external-beam radiotherapy within the context of&#xD;
             a formal clinical study for any of the following:&#xD;
&#xD;
               -  Early breast cancer after breast-conserving surgery&#xD;
&#xD;
               -  Localized prostate cancer&#xD;
&#xD;
               -  Gynecological cancer (may have also received brachytherapy)&#xD;
&#xD;
          -  Venous blood samples must be available&#xD;
&#xD;
          -  Patients will be identified from the following clinical studies:&#xD;
&#xD;
               -  Cambridge intensity-modulated radiotherapy breast randomized trial&#xD;
&#xD;
               -  RT01 prostate radiotherapy randomized trial/other prostate trials&#xD;
&#xD;
               -  Christie hospital breast, prostate, and gynecological cancer radiotherapy&#xD;
                  patients&#xD;
&#xD;
          -  Must have minimum follow up with late normal tissue effect scoring for two years&#xD;
             available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  No other malignancy prior to treatment for the specified tumor types except basal cell&#xD;
             or squamous cell carcinoma of the skin or in situ carcinoma&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine West</last_name>
    <role>Study Chair</role>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sussex Cancer Centre at Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <state>England</state>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-12-7369-6955</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-117-928-2415</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1223-336-800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <state>England</state>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1473-704-177</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-161-446-8275</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-151-334-1155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Whiston Hospital</name>
      <address>
        <city>Prescot</city>
        <state>England</state>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-151-334-1155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research Centre at Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S1O 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-114-226-5000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southport and Formby District General Hospital</name>
      <address>
        <city>Southport</city>
        <state>England</state>
        <zip>PR8 6PN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-151-334-1155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-8661-3271</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Warrington Hospital NHS Trust</name>
      <address>
        <city>Warrington</city>
        <state>England</state>
        <zip>WA5 1QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-151-334-1155</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>January 25, 2008</study_first_submitted>
  <study_first_submitted_qc>January 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>male breast cancer</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IA cervical cancer</keyword>
  <keyword>stage IB cervical cancer</keyword>
  <keyword>stage IIA cervical cancer</keyword>
  <keyword>stage IIB cervical cancer</keyword>
  <keyword>stage III cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <keyword>stage I vaginal cancer</keyword>
  <keyword>stage II vaginal cancer</keyword>
  <keyword>stage III vaginal cancer</keyword>
  <keyword>stage IVA vaginal cancer</keyword>
  <keyword>stage IVB vaginal cancer</keyword>
  <keyword>stage IA vulvar cancer</keyword>
  <keyword>stage IB vulvar cancer</keyword>
  <keyword>stage II vulvar cancer</keyword>
  <keyword>stage IIIC vulvar cancer</keyword>
  <keyword>stage IIIA vulvar cancer</keyword>
  <keyword>stage IIIB vulvar cancer</keyword>
  <keyword>stage IVB vulvar cancer</keyword>
  <keyword>stage IA ovarian epithelial cancer</keyword>
  <keyword>stage IB ovarian epithelial cancer</keyword>
  <keyword>stage IC ovarian epithelial cancer</keyword>
  <keyword>stage IA ovarian germ cell tumor</keyword>
  <keyword>stage IB ovarian germ cell tumor</keyword>
  <keyword>stage IC ovarian germ cell tumor</keyword>
  <keyword>stage IIA ovarian epithelial cancer</keyword>
  <keyword>stage IIB ovarian epithelial cancer</keyword>
  <keyword>stage IIC ovarian epithelial cancer</keyword>
  <keyword>stage IIA ovarian germ cell tumor</keyword>
  <keyword>stage IIB ovarian germ cell tumor</keyword>
  <keyword>stage IIC ovarian germ cell tumor</keyword>
  <keyword>stage IIIA ovarian epithelial cancer</keyword>
  <keyword>stage IIIB ovarian epithelial cancer</keyword>
  <keyword>stage IIIC ovarian epithelial cancer</keyword>
  <keyword>stage IIIA ovarian germ cell tumor</keyword>
  <keyword>stage IIIB ovarian germ cell tumor</keyword>
  <keyword>stage IIIC ovarian germ cell tumor</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>stage II endometrial carcinoma</keyword>
  <keyword>ovarian stromal cancer</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>stage IA fallopian tube cancer</keyword>
  <keyword>stage IB fallopian tube cancer</keyword>
  <keyword>stage IC fallopian tube cancer</keyword>
  <keyword>stage IIA fallopian tube cancer</keyword>
  <keyword>stage IIB fallopian tube cancer</keyword>
  <keyword>stage IIC fallopian tube cancer</keyword>
  <keyword>stage IIIA fallopian tube cancer</keyword>
  <keyword>stage IIIB fallopian tube cancer</keyword>
  <keyword>stage IIIC fallopian tube cancer</keyword>
  <keyword>stage IV fallopian tube cancer</keyword>
  <keyword>recurrent primary peritoneal cavity cancer</keyword>
  <keyword>stage IA primary peritoneal cavity cancer</keyword>
  <keyword>stage IB primary peritoneal cavity cancer</keyword>
  <keyword>stage IC primary peritoneal cavity cancer</keyword>
  <keyword>stage IIA primary peritoneal cavity cancer</keyword>
  <keyword>stage IIB primary peritoneal cavity cancer</keyword>
  <keyword>stage IIC primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIA primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIB primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIC primary peritoneal cavity cancer</keyword>
  <keyword>stage IV primary peritoneal cavity cancer</keyword>
  <keyword>stage IA endometrial carcinoma</keyword>
  <keyword>stage IB endometrial carcinoma</keyword>
  <keyword>stage IIIA endometrial carcinoma</keyword>
  <keyword>stage IIIB endometrial carcinoma</keyword>
  <keyword>stage IIIC endometrial carcinoma</keyword>
  <keyword>stage IVA endometrial carcinoma</keyword>
  <keyword>stage IVB endometrial carcinoma</keyword>
  <keyword>stage IA uterine sarcoma</keyword>
  <keyword>stage IB uterine sarcoma</keyword>
  <keyword>stage IC uterine sarcoma</keyword>
  <keyword>stage IIA uterine sarcoma</keyword>
  <keyword>stage IIB uterine sarcoma</keyword>
  <keyword>stage IIIA uterine sarcoma</keyword>
  <keyword>stage IIIB uterine sarcoma</keyword>
  <keyword>stage IIIC uterine sarcoma</keyword>
  <keyword>stage IVA uterine sarcoma</keyword>
  <keyword>stage IVB uterine sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

